Skip to main content
Premium Trial:

Request an Annual Quote

Lansing Taylor, David Dodd

The board of directors of the Pittsburgh Life Sciences Greenhouse has approved the nomination of Lansing Taylor as chairman. He takes over for co-chairs Mark Nordenberg and Jared Cohon.
 
Taylor is already on the board of PLSG and recently served as chairman and CEO of high-content cell screening firm Cellomics, which he founded and was acquired by Thermo Fisher Scientific in September 2005. He also was a co-founder, member of the board, and scientific advisor to Biological Detection Systems, which was sold to Amersham Biosciences in 1996.
 

 
BioReliance has tapped David Dodd to be president, CEO, and chairman of the company’s board of directors.
 
Dodd formerly was president and CEO of Serologicals and prior to that he was president and CEO of Solvay Pharmaceuticals. Dodd also formerly was employed at Abbott Laboratories, Bristol-Myers Squibb, and McDonnell-Douglas Healthcare Systems.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.